Which of the following best describes the pathophysiology behind vascular calcifications in CKD-MBD?

• A. Decreased phosphate absorption from the gut
• B. Elevated calcitonin levels
• C. Use of calcium-based phosphate binders contributing to calcification
• D. Overproduction of vitamin D by immune cells

Answer: (C)

In CKD-MBD, the vascular system calcifies mainly because phosphate builds up outside the bones and combines with calcium, pushing the calcium-phosphate product toward levels that precipitate in vessel walls. As kidney function declines, phosphate excretion drops, causing hyperphosphatemia. Vascular smooth muscle cells sense high extracellular phosphate and can undergo an osteogenic transformation, producing bone-like matrix and promoting calcium phosphate deposition in the vessels.

Calcium-based phosphate binders add extra calcium to the system. That increases both the total calcium load and the calcium-phosphate product, making it easier for calcium phosphate crystals to form in the vasculature. This is why these binders can contribute to vascular calcification, and why non-calcium binders are often favored to limit calcium burden.

Options about decreased gut phosphate absorption, elevated calcitonin, or overproduction of vitamin D by immune cells don’t fit this dominant mechanism. Decreased phosphate absorption would not drive the high phosphate levels seen in CKD; calcitonin lowers calcium, not promotes calcification; and vitamin D is not overproduced by immune cells in this context—lunging toward dysregulated vitamin D metabolism in CKD usually involves deficiency or resistance rather than excess production.